Market Summary
USD185.56-4.82
Market Closed-2.53%
BGNE Stock Price
BGNE RSI Chart
BGNE Valuation
BGNE Price/Sales (Trailing)
BGNE Profitability
BGNE Fundamentals
BGNE Revenue
BGNE Earnings
Price Action
52 Week Range
124.46280.62
(Low)(High)
Last 7 days
-11.2%
Last 30 days
-6.5%
Last 90 days
3.2%
Trailing 12 Months
40.8%
BGNE Financial Health
BGNE Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BGNE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-31 | Lee Chan Henry | sold | -171,059 | 216 | -791 | svp, general counsel |
2023-07-03 | Wang Julia Aijun | sold | -84,747 | 179 | -472 | chief financial officer |
2023-06-26 | Wang Lai | sold | -201,567 | 181 | -1,108 | global head of r&d |
2023-06-26 | Wu Xiaobin | sold | -272,636 | 182 | -1,495 | president, coo & gm china |
2023-06-23 | Wang Julia Aijun | sold | -153,594 | 182 | -840 | chief financial officer |
2023-06-23 | Sanders Corazon (Corsee) D. | sold | -105,381 | 182 | -578 | - |
2023-06-20 | Wang Lai | sold | -254,955 | 192 | -1,325 | global head of r&d |
2023-06-20 | Wu Xiaobin | sold | -337,356 | 192 | -1,753 | president, coo & gm china |
2023-06-20 | Wang Julia Aijun | sold | -36,583 | 192 | -190 | chief financial officer |
2023-06-15 | BAKER BROS. ADVISORS LP | acquired | - | - | 51,688 | - |
Which funds bought or sold BGNE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 1,058 | 165,000 | 184,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -707 | 3,388 | -% |
2023-08-24 | Alberta Investment Management Corp | new | - | 486,224 | 486,224 | -% |
2023-08-22 | Old North State Trust, LLC | sold off | -100 | -4,000 | - | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | sold off | -100 | -258,636 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 2.47 | -55,140 | 304,654 | -% |
2023-08-21 | BOKF, NA | sold off | -100 | -3,017 | - | -% |
2023-08-16 | Thomas J. Herzfeld Advisors, Inc. | unchanged | - | -819 | 3,923 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 163 | 5,131,560 | 9,485,560 | -% |
2023-08-15 | PIN OAK INVESTMENT ADVISORS INC | new | - | 1,000 | 1,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of BeiGene
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 05, 2023 | baker bros. advisors lp | 11.2% | 152,522,377 | SC 13D/A | |
| Feb 14, 2023 | hhlr advisors, ltd. | 10.9% | 147,043,058 | SC 13D/A | |
| Feb 13, 2023 | capital international investors | 8.2% | 110,215,170 | SC 13G/A | |
| Feb 10, 2023 | oyler john | 5.1% | 70,026,397 | SC 13G/A | |
| Aug 16, 2022 | hhlr advisors, ltd. | 10.9% | 147,035,258 | SC 13D/A | |
| Feb 14, 2022 | oyler john | 5.1% | 69,558,605 | SC 13G/A | |
| Feb 11, 2022 | capital international investors | 7.8% | 104,036,177 | SC 13G/A | |
| Feb 11, 2022 | beigene, ltd. | 5.1% | 69,558,605 | SC 13G/A | |
| Feb 11, 2022 | invesco ltd. | 5.6% | 39,028,821 | SC 13G | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Recent SEC filings of BeiGene
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 21, 2023 | 8-K | Current Report | |
| Sep 19, 2023 | 8-K | Current Report | |
| Aug 29, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 10-Q | Quarterly Report | |
| Aug 02, 2023 | 4 | Insider Trading | |
| Aug 02, 2023 | 8-K | Current Report | |
| Jul 31, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 24, 2023 | 8-K | Current Report | |
| Jul 11, 2023 | 8-K | Current Report | |
| Jul 06, 2023 | 4 | Insider Trading |
Peers (Alternatives to BeiGene)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 272.0B | 56.0B | 4.92% | 10.10% | 31.31 | 4.85 | -2.31% | -31.27% |
BGNE | 255.4B | 1.8B | -6.48% | 40.79% | -147.41 | 141.03 | 69.45% | 14.65% |
VRTX | 90.7B | 9.5B | 0.47% | 27.06% | 26.94 | 9.54 | 13.83% | 5.33% |
REGN | 89.1B | 12.7B | 0.25% | 21.32% | 20.72 | 7.03 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.51% | -11.32% | -20.56 | 17.67 | 39.94% | -8.44% |
SRPT | 11.1B | 1.0B | 0.34% | 12.49% | -12.27 | 11.1 | 20.15% | -79.16% |
UTHR | 10.8B | 2.1B | 0.39% | 13.09% | 12.38 | 5.11 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | -1.27% | -20.90% | -5.46 | 13.42 | -2.11% | 21.02% |
MDGL | 2.7B | - | -16.94% | 136.35% | -8.34 | - | - | -28.88% |
RARE | 2.7B | 402.9M | -1.32% | -6.38% | -3.71 | 6.64 | 20.50% | -42.46% |
MRTX | 2.4B | 27.2M | 9.81% | -39.54% | -3.22 | 87.12 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -13.94% | -37.40% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -14.75% | 0.41% | 11.19 | 4.27 | 77.72% | 112.02% |
MGNX | 295.4M | 152.5M | -5.54% | 48.60% | 39.66 | 1.94 | 127.84% | 103.41% |
CRBP | 28.4M | - | -5.44% | 3918.75% | -0.62 | - | - | -31.51% |
BeiGene News
Returns for BGNE
Cumulative Returns on BGNE
30.1%
7-Year Cumulative Returns
1.5%
5-Year Cumulative Returns
-13.1%
3-Year Cumulative Returns
Risks for BGNE
What is the probability of a big loss on BGNE?
100%
Probability that BeiGene stock will be more than 20% underwater in next one year
75.4%
Probability that BeiGene stock will be more than 30% underwater in next one year.
33.9%
Probability that BeiGene stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BGNE drawdown profile look like?
Y-axis is the maximum loss one would have experienced if BeiGene was unfortunately bought at previous high price.
Drawdowns
Financials for BeiGene
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 16.3% | 1,810,785,000 | 1,557,096,000 | 1,415,921,000 | 1,249,805,000 | 1,068,617,000 | 877,037,000 | 1,176,283,000 | 1,062,404,000 | 947,044,000 | 862,687,000 | 308,874,000 | 265,666,000 | 224,727,000 | 402,438,000 | 428,212,000 | 429,990,000 | 434,051,000 | 243,509,000 | 198,220,000 | 157,724,000 | 323,735,000 |
| S&GA Expenses | 4.9% | 1,375,409,000 | 1,311,778,000 | 1,277,852,000 | 1,255,369,000 | 1,201,704,000 | 1,102,590,000 | 990,123,000 | 891,831,000 | 783,441,000 | 675,201,000 | 600,176,000 | 535,321,000 | 479,486,000 | 437,685,000 | 388,249,000 | 317,385,000 | 261,203,000 | 224,115,000 | 195,385,000 | 150,310,000 | 117,131,000 |
| R&D Expenses | 2.7% | 1,703,734,000 | 1,659,177,000 | 1,640,508,000 | 1,624,970,000 | 1,550,544,000 | 1,528,428,000 | 1,459,239,000 | 1,384,291,000 | 1,381,424,000 | 1,311,301,000 | 1,294,877,000 | 1,222,599,000 | 1,110,497,000 | 1,053,289,000 | 927,338,000 | 901,543,000 | 812,165,000 | 747,656,000 | 679,005,000 | 512,881,000 | 452,951,000 |
| EBITDA | 100.0% | - | -1,748,613,000 | -1,842,279,000 | -2,025,714,000 | -1,926,567,000 | -1,870,492,000 | -1,407,888,000 | -1,309,765,000 | -1,313,727,000 | -1,168,144,000 | -1,584,407,000 | -1,478,361,000 | -1,356,700,000 | -1,105,126,000 | -915,838,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -1.12 | -1.30 | -1.62 | -1.80 | -2.13 | -1.20 | -1.23 | -1.39 | -1.35 | -5.13 | -5.56 | -6.04 | -2.75 | -2.14 | - | - | - | - | - | - |
| Interest Expenses | 6.2% | 62,064,000 | 58,425,000 | 52,480,000 | 29,779,000 | 14,790,000 | -1,507,000 | -15,757,000 | -16,461,000 | -14,845,000 | -8,871,000 | 1,998,000 | 6,746,000 | 9,566,000 | 11,344,000 | 9,131,000 | 15,519,000 | 17,866,000 | 16,872,000 | 13,947,000 | 7,470,000 | 1,132,000 |
| Earnings Before Taxes | 10.1% | -1,686,605,000 | -1,876,727,000 | -1,961,037,000 | -2,116,876,000 | -1,998,716,000 | -1,921,702,000 | -1,438,588,000 | -1,333,760,000 | -1,335,722,000 | -1,192,944,000 | -1,618,194,000 | -1,516,552,000 | -1,393,389,000 | -1,139,421,000 | -943,586,000 | -838,506,000 | -671,593,000 | -748,851,000 | -689,829,000 | -508,940,000 | -249,753,000 |
| EBT Margin | 100.0% | - | -1.21 | -1.38 | -1.69 | -1.87 | -2.19 | -1.22 | -1.26 | -1.41 | -1.38 | -5.24 | -5.71 | -6.20 | -2.83 | -2.20 | - | - | - | - | - | - |
| Net Income | 9.6% | -1,732,459,000 | -1,917,048,000 | -2,003,815,000 | -2,149,158,000 | -2,029,716,000 | -1,948,594,000 | -1,457,816,000 | -1,339,883,000 | -1,326,993,000 | -1,178,707,000 | -1,599,226,000 | -1,514,542,000 | -1,396,675,000 | -1,145,927,000 | -948,628,000 | -828,822,000 | -665,496,000 | -736,813,000 | -673,769,000 | -504,837,000 | -243,420,000 |
| Net Income Margin | 100.0% | - | -1.23 | -1.42 | -1.72 | -1.86 | -2.18 | -1.20 | -1.22 | -1.39 | -1.35 | -5.17 | -5.69 | -6.20 | -2.84 | -2.22 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -2,229,721,000 | -1,822,053,000 | -2,005,322,000 | -1,897,517,000 | -1,926,065,000 | -1,561,665,000 | -1,305,870,000 | -1,118,036,000 | -954,786,000 | -1,400,969,000 | -1,316,591,000 | -1,237,554,000 | -1,009,555,000 | -839,881,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -3.8% | 5,729 | 5,957 | 6,379 | 6,726 | 7,378 | 8,021 | 8,536 | 5,286 | 5,524 | 5,821 | 5,601 | 5,566 | 3,903 | 4,067 | 1,612 | 1,881 | 2,150 | 2,172 | 2,250 | 2,409 | 1,654 |
| Current Assets | -6.4% | 4,401 | 4,704 | 5,207 | 5,749 | 6,346 | 6,948 | 7,614 | 4,433 | 4,799 | 5,141 | 4,961 | 4,966 | 3,392 | 3,595 | 1,173 | 1,436 | 1,756 | 1,797 | 1,944 | 2,180 | 1,517 |
| Cash Equivalents | -3.6% | 3,410 | 3,539 | 3,870 | 4,197 | 4,531 | 4,347 | 4,383 | 1,383 | 1,776 | 1,902 | 1,382 | 1,464 | 1,345 | 1,957 | 621 | 857 | 919 | 764 | 741 | 643 | 438 |
| Inventory | 8.2% | 321 | 297 | 282 | 291 | 262 | 246 | 243 | 151 | 118 | 73.00 | 89.00 | 36.00 | 33.00 | 29.00 | 29.00 | 38.00 | 49.00 | 13.00 | 16.00 | 20.00 | 6.00 |
| Net PPE | 11.5% | 1,032 | 925 | 846 | 682 | 633 | 625 | 588 | 451 | 395 | 374 | 358 | 291 | 258 | 240 | 242 | 226 | 213 | 198 | 157 | 111 | 91.00 |
| Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | 7.3% | 1,930 | 1,799 | 1,996 | 2,071 | 2,076 | 2,136 | 2,403 | 1,929 | 1,917 | 1,817 | 1,732 | 1,270 | 1,357 | 1,240 | 634 | 587 | 579 | 550 | 496 | 425 | 427 |
| Current Liabilities | 12.0% | 1,405 | 1,255 | 1,469 | 1,411 | 1,398 | 1,376 | 1,600 | 1,304 | 1,242 | 1,113 | 1,075 | 646 | 551 | 452 | 310 | 266 | 272 | 239 | 246 | 188 | 186 |
| LT Debt, Current | -78.2% | 421 | 1,935 | 2,269 | 441 | 2,550 | 407 | 428 | 2,850 | 2,807 | 405 | 335 | 50.00 | 26.00 | 11.00 | - | 1.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 |
| LT Debt, Non Current | 0.5% | 207 | 206 | 209 | 208 | 185 | 202 | 1,288 | 201 | 195 | 1,265 | 1,198 | 152 | 131 | 82.00 | 580 | 104 | 84.00 | 77.00 | 41.00 | 41.00 | 51.00 |
| Shareholder's Equity | -8.6% | 3,799 | 4,157 | 4,383 | 4,655 | 5,197 | 5,774 | 6,133 | 3,252 | 3,526 | 3,927 | 3,803 | 4,297 | 2,546 | 2,827 | 940 | 1,294 | 1,571 | 1,623 | 1,754 | 1,983 | 1,227 |
| Retained Earnings | -5.1% | -7,809 | -7,428 | -7,080 | -6,635 | -5,971 | -5,400 | -5,076 | -4,380 | -3,966 | -3,486 | -3,552 | -3,080 | -2,654 | -2,319 | -1,955 | -1,567 | -1,260 | -1,174 | -1,007 | -738 | -594 |
| Additional Paid-In Capital | 0.9% | 11,752 | 11,645 | 11,541 | 11,452 | 11,357 | 11,268 | 11,191 | 7,725 | 7,561 | 7,487 | 7,415 | 7,368 | 5,200 | 5,138 | 2,926 | 2,861 | 2,814 | 2,777 | 2,745 | 2,710 | 1,805 |
| Shares Outstanding | 1.0% | 1,376 | 1,363 | 1,356 | 1,350 | 1,336 | 1,332 | 1,335 | 1,206 | 1,194 | 1,189 | 1,191 | 1,149 | 1,010 | 1,005 | 801 | 781 | 776 | 775 | 721 | 703 | 699 |
| Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | 9.00 | 10.00 | 15.00 | 16.00 | 16.00 | 17.00 | 14.00 | 14.00 | 13.00 | 13.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 4.7% | -1,737 | -1,823 | -1,496 | -1,686 | -1,620 | -1,660 | -1,298 | -1,123 | -973 | -816 | -1,283 | -1,218 | -1,137 | -920 | -750 | -676 | -544 | -615 | -547 | -260 | -121 |
| Share Based Compensation | 7.1% | 335 | 313 | 303 | 288 | 277 | 260 | 241 | 227 | 210 | 191 | 183 | 172 | 159 | 146 | 134 | 122 | 110 | 96.00 | 87.00 | 78.00 | 66.00 |
| Cashflow From Investing | -53.3% | 517 | 1,108 | 1,077 | 1,148 | 966 | 559 | 641 | 445 | -1,079 | -1,761 | -3,168 | -3,105 | -1,355 | -733 | 554 | 791 | 87.00 | -70.84 | -637 | -919 | -829 |
| Cashflow From Financing | 666.1% | 156 | -27.57 | -18.97 | 3,476 | 3,465 | 3,518 | 3,637 | 578 | 2,463 | 2,508 | 5,203 | 4,879 | 2,910 | 2,845 | 86.00 | 92.00 | 938 | 970 | 1,691 | 1,685 | 1,153 |
BGNE Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues | ||||
| Total revenues | $ 595,261 | $ 341,572 | $ 1,043,062 | $ 648,198 |
| Expenses | ||||
| Cost of sales - product | 95,990 | 71,173 | 177,779 | 136,410 |
| Research and development | 422,764 | 378,207 | 831,348 | 768,122 |
| Selling, general and administrative | 395,034 | 331,403 | 723,533 | 625,976 |
| Amortization of intangible assets | 188 | 188 | 375 | 376 |
| Total expenses | 913,976 | 780,971 | 1,733,035 | 1,530,884 |
| Loss from operations | (318,715) | (439,399) | (689,973) | (882,686) |
| Interest income, net | 15,070 | 11,431 | 31,086 | 21,502 |
| Other expense, net | (63,818) | (129,617) | (45,515) | (117,650) |
| Loss before income taxes | (367,463) | (557,585) | (704,402) | (978,834) |
| Income tax expense | 13,674 | 8,141 | 25,166 | 22,090 |
| Net loss | $ (381,137) | $ (565,726) | $ (729,568) | $ (1,000,924) |
| Net loss per share, basic (in dollars per share) | $ (0.28) | $ (0.42) | $ (0.54) | $ (0.75) |
| Net loss per share, diluted (in dollars per share) | $ (0.28) | $ (0.42) | $ (0.54) | $ (0.75) |
| Weighted-average shares outstanding—basic (in shares) | 1,360,224,377 | 1,336,463,026 | 1,357,211,308 | 1,334,252,648 |
| Weighted-average shares outstanding - diluted (in shares) | 1,360,224,377 | 1,336,463,026 | 1,357,211,308 | 1,334,252,648 |
| Net loss per American Depositary Share ("ADS") basic (in dollars per share) | $ (3.64) | $ (5.50) | $ (6.99) | $ (9.75) |
| Net loss per American Depositary Share ("ADS") diluted (in dollars per share) | $ (3.64) | $ (5.50) | $ (6.99) | $ (9.75) |
| Weighted-average ADSs outstanding - basic (in shares) | 104,632,644 | 102,804,848 | 104,400,870 | 102,634,819 |
| Weighted-average ADSs outstanding - diluted (in shares) | 104,632,644 | 102,804,848 | 104,400,870 | 102,634,819 |
| Product revenue, net | ||||
| Revenues | ||||
| Total revenues | $ 553,745 | $ 304,511 | $ 964,036 | $ 566,084 |
| Collaboration revenue | ||||
| Revenues | ||||
| Total revenues | $ 41,516 | $ 37,061 | $ 79,026 | $ 82,114 |
BGNE Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,410,368 | $ 3,869,564 |
| Short-term restricted cash | 9,693 | 196 |
| Short-term investments | 105,693 | 665,251 |
| Accounts receivable, net | 299,282 | 173,168 |
| Inventories | 321,333 | 282,346 |
| Prepaid expenses and other current assets | 255,050 | 216,553 |
| Total current assets | 4,401,419 | 5,207,078 |
| Long-term restricted cash | 1,513 | 5,277 |
| Property, plant and equipment, net | 1,031,938 | 845,946 |
| Operating lease right-of-use assets | 99,422 | 109,960 |
| Intangible assets, net | 46,895 | 40,616 |
| Other non-current assets | 147,549 | 170,413 |
| Total non-current assets | 1,327,317 | 1,172,212 |
| Total assets | 5,728,736 | 6,379,290 |
| Current liabilities: | ||
| Accounts payable | 266,975 | 294,781 |
| Accrued expenses and other payables | 454,950 | 467,352 |
| Deferred revenue, current portion | 159,034 | 213,861 |
| Tax payable | 17,074 | 25,189 |
| Operating lease liabilities, current portion | 23,508 | 24,041 |
| Research and development cost share liability, current portion | 62,516 | 114,335 |
| Short-term debt | 421,052 | 328,969 |
| Total current liabilities | 1,405,109 | 1,468,528 |
| Non-current liabilities: | ||
| Long-term bank loans | 207,426 | 209,148 |
| Deferred revenue, non-current portion | 24,276 | 42,026 |
| Operating lease liabilities, non-current portion | 25,821 | 34,517 |
| Deferred tax liabilities | 15,652 | 15,996 |
| Research and development cost share liability, non-current portion | 208,775 | 179,625 |
| Other long-term liabilities | 43,118 | 46,095 |
| Total non-current liabilities | 525,068 | 527,407 |
| Total liabilities | 1,930,177 | 1,995,935 |
| Commitments and contingencies | ||
| Equity: | ||
| Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,376,251,336 and 1,356,140,180 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 137 | 135 |
| Additional paid-in capital | 11,752,019 | 11,540,979 |
| Accumulated other comprehensive loss | (143,687) | (77,417) |
| Accumulated deficit | (7,809,910) | (7,080,342) |
| Total equity | 3,798,559 | 4,383,355 |
| Total liabilities and equity | $ 5,728,736 | $ 6,379,290 |
BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Beijing, China.